Trial · Interventional

Not yet recruitingPhase 3Registry data

Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Women With PCOS Undergoing PGT-A

NCTNCT05326087Other idJIAI 2022-03

Open at ClinicalTrials.govAsk about this trial

Overview

Status: Not yet recruiting
Phase: Phase 3
Enrollment: 204 participants (estimated)
Sponsor: ShangHai Ji Ai Genetics & IVF Institute · Other
Design: Randomized · Open label (no masking)
Countries: Not stated
Start: 1 Jun 2026 (estimated)
Primary completion: 1 Dec 2027 (estimated)
Completion: 1 Dec 2028 (estimated)
First posted: 13 Apr 2022
Last update posted: 2 Feb 2026
Conditions: Preimplantation Genetic Testing · Progestin-primed Ovarian Stimulation · Polycystic Ovarian Syndrome · GnRH Antagonist

Timeline

1 trial · 1 not yet recruiting

Completed
Ongoing
Not yet recruiting
Stopped
Estimated dates (est.)
Results posted

2026202720282029

Ph 3
Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Women With PCOS Undergoing PGT-A
NCT05326087
est. 1 Jun 2026 to est. 1 Dec 2028

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

This randomized trial aims to compare the euploid rate of blastocysts between PPOS (progestin-primed ovarian stimulation) and GnRH (gonadotrophin releasing hormone) antagonist protocols in patients with PCOS (polycystic ovary syndrome) undergoing PGT-A (preimplantation genetic testing for aneuploidy). Infertile women with PCOS will be recruited for study after explanation and counseling if they fulfill the inclusion criteria and do not have the exclusion criteria. Eligible women will be randomised into one of the two groups: Antagonist group: Women will receive antagonist once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger. PPOS group: Women will receive oral MPA (medroxyprogesterone acetate)10mg qd from Day 3 till the day of ovulation trigger. The primary outcome is the euploidy rate of blastocysts.

Interventions

GnRH antagonistDrug
MPADrug

Arms2

Active comparator
Antagonist group
Women will receive antagonist (Cetrotide 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger.
Experimental
PPOS group
Women will receive oral MPA 10mg qd from Day 3 till the day of ovulation trigger.

Primary outcomes1

Outcomes the sponsor listed as primary.

euploidy rate
Time frame · 1 month after oocyte retrieval
Registry description
euploidy rate of blastocysts

Secondary outcomes(6)

live birth rate
Time frame · 1 year after embryo transfer
Registry description
deliveries ≥22 weeks gestation with heartbeat and breath of the first frozen embryo transfer
cumulative live birth rate
Time frame · 1 year after embryo transfer
Registry description
cumulative live birth within 6 months of randomization
ongoing pregnancy
Time frame · 12 weeks' gestation
Registry description
a viable pregnancy beyond 12 weeks' gestation of the first frozen embryo transfer
number of oocytes retrieved
Time frame · 1 day after oocyte retrieval
Registry description
number of oocytes retrieved
OHSS（ovarian hyperstimulation syndrome）
Time frame · 1 month after ovarian stimulation
Registry description
Moderate or severe ovarian hyperstimulation syndrome.Ovarian hyperstimulation syndrome (OHSS) is diagnosed and classified according to the Royal College of Obstetricians and Gynaecologists guideline. Green-top guideline No.5. Ovarian hyperstimulation syndrome. https://www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg5/ (accessed 26 Feb 2016).
birthweight of newborns
Time frame · 1 year after embryo transfer
Registry description
birthweight of newborns

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

A trial that is still running, or that stopped early, may post results later.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies1

Studies that cite this trial.

Studies with results

1 study on this page

Indexing hint: Randomized controlled trial · 2019

9 results

Medroxyprogesterone acetate versus ganirelix in oocyte donation: a randomized controlled trial.

Beguería et al. 2019Human reproduction (Oxford, England)cited by 80

PMID 30927417DOI 10.1093/humrep/dez034PUB-30927417

Full text at the publisher9 results

Publisher page See results (9)

Eligibility

Who could join, as posted.

Sex: Female
Age: from 20 Years up to 37 Years
Healthy volunteers: Not accepted

Inclusion and exclusion criteria, as posted

Inclusion Criteria: * Women age between 20 and 37 years. * Women diagnosed with PCOS according to the modified Rotterdam criteria: oligomenorrhea or amenorrhea, together with the presence of ≥12 antral follicles (≤9 mm) and/or ovarian volume \>10 mL on transvaginal ultrasonographic scanning, and/or clinical/ biochemical hyperandrogenism. Other causes of hyperandrogenism and ovulation dysfunction-including tumours, congenital adrenal hyperplasia, hyperprolactinaemia and thyroid dysfunction-were excluded Exclusion Criteria: * Presence of a functional ovarian cyst with E2\>100 pg/mL * Endometriosis grade 3 or higher * Repeated implantation failure (\>=4 embryos replaced or \>=2 blastocysts replaced without success) * Women with a uterine cavity abnormality, such as a uterine congenital malformation (uterus uni-cornate, bicornate, or duplex); untreated uterine septum, adenomyosis, submucous myoma, or endo-metrial polyp(s) * Women who are indicated and planned to undergo PGT-SR (Preimplantation genetic testing for structural rearrangement) or PGT-M (Preimplantation genetic testing for monogenic disorder), for example, parental abnormal karyo-type or diagnosed with monogenic disease; * Recipient of oocyte donation * Presence of hydrosalpinx which is not surgically treated

PepBank is a research reference. Talk to a doctor before you use any peptide.